Dabrafenib, trametinib found more effective in pediatric glioma with BRAF V600

September 21 2023, by Elana Gotkine

Dabrafenib plus trametinib results in significantly more responses and
longer progression-free survival than standard chemotherapy for pediatric patients with low-grade glioma with BRAF V600 mutations, according to a study published in the Sept. 21 issue of the *New England Journal of Medicine*.

Eric Bouffet, M.D., from The Hospital for Sick Children in Toronto, and colleagues conducted a phase 2 trial involving patients with pediatric low-grade glioma with BRAF V600 mutations who were scheduled to receive first-line therapy. In total, 110 patients were randomly assigned to receive dabrafenib plus trametinib or standard chemotherapy (carboplatin plus vincristine; 73 and 37 patients, respectively). The independently assessed overall response (complete or partial response) according to the Response Assessment in Neuro-Oncology criteria was examined as the primary outcome.

The researchers found that an overall response occurred in 47% and 11% of those treated with dabrafenib plus trametinib and those treated with chemotherapy, respectively, at a median follow-up of 18.9 months (risk ratio, 4.31). Clinical benefit was observed in 86% and 46% of patients receiving dabrafenib plus trametinib and chemotherapy, respectively (risk ratio, 1.88). Significantly longer median progression-free survival was seen with dabrafenib plus trametinib versus chemotherapy (20.1 versus 7.4 months; hazard ratio, 0.31). Grade 3 or higher adverse events occurred in 47% and 94% of those receiving dabrafenib plus trametinib and chemotherapy, respectively.

"Overall, these findings show the value of early molecular testing in children with low-grade glioma to determine the presence or absence of BRAF V600 mutations," the authors write.

Citation: Dabrafenib, trametinib found more effective in pediatric glioma with BRAF V600 (2023, September 21) retrieved 26 September 2023 from https://medicalxpress.com/news/2023-09-dabrafenib-trametinib-effective-pediatric-glioma.html